

Project Title: Innovation of photonic and electrochemical biosensors for cholangiocarcinoma diagnosis

Speaker:

Prof. Somchai Pinlaor, et al.,

Project Duration :

24 months

First Year : May 1st , 2023 to April 30th , 2024

Second Year: May 1st , 2024 to April 30th , 2025

Project Budget:

80,000 USD

First Year : 40,000 USD

Second Year: 40,000 USD

25 Sep 2025, BBK, Thailand

Project Title: Innovation of photonic and electrochemical biosensors for cholangiocarcinoma diagnosis

Project members

7 institutes, 3 countries

KKU (THA) : Somchai Pinlaor, Chavis Srichan,
Pobporn Danvirutai, Kitti Intuyod, Apisit Chaidee,
Sirinapha Klungsaeng

CMU (THA) : Ukrit Mankong, Suruk Udomsom

TMEC : Nithi Atthi


BIOTEC : Sittiruk Roytrakul, Janthima Jaresitthikunchai,
Narumon Phaonakrop

NECTEC : Noppadon Nuntawong, Mati Horprathum, Pitak
Eiamchai, Saksorn Limwichean

Mittaphab Hospital (LAO) : Champadeng Vongdala,
Keooudone Thammavong

NICT (JPN) : Toshimasa Umezawa, Atsushi Matsumoto,
Kouichi Akahane


Project management




Workspace of project management

Project title: Innovation of photonic and electrochemical biosensors for cholangiocarcinoma diagnosis


Background



Banales. J.M. et al, 2020



Khuntikeo N et al. 2018



Sripa B et al. 2011

Current diagnostic techniques

Tumor screening




Ultrasound

Confirmation



MRI

Tumor type identifying & staging



Tissue biopsy



Tumor markers: CA19-9, CEA, AFP

CA 19-9 (Carbohydrate Antigen 19-9), CEA (Carcinoembryonic Antigen), and AFP (Alpha-fetoprotein)

Project title: Innovation of photonic and electrochemical biosensors for cholangiocarcinoma diagnosis

Previous finding

O. viverrini infection contributes to CCA development




Fig.1 OV-induced inflammation, fibrosis, advanced fibrosis, and contribution risk to CCA. Thus, radiology such as MRI & Ultrasound are used for CCA screening.

Our hypothesis

CCA development is cell-types specific.




Fig.2 OV-induced chronic inflammation, precancerous lesion and CCA development

Project title: Innovation of photonic and electrochemical biosensors for cholangiocarcinoma diagnosis

Challenge



Early-stage diagnosis of bladder cancer using surface-enhanced Raman spectroscopy combined with machine learning algorithms in a rat model


Sanghwa Lee^{a,1}, Miyeon Jue^{a,b,1}, Kwanhee Lee^c, Bjorn Paulson^{a,d}, Jeongmin Oh^c, Minju Cho^c, Jun Ki Kim^{a,1,*}

^a Biomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea


^b Apollon, Inc., 68 Achaean-ro, Seongdong-gu, Seoul, 05505, Republic of Korea

^c Department of Biomedical Engineering, College of Medicine, University of Ulsan, Seoul, 05505, Republic of Korea


^d Morgridge Institute for Research, Madison, WI, 53715, USA



Silicon photonic sensor




Raman spectroscopy



NECTEC SERs Chips

+



Convolutional neuron network, CNN

Target

To develop photonic and electrochemical biosensors for cholangiocarcinoma diagnosis

Hamster's CCA establishment for hypothesis testing




Fig.3 Schematic diagram illustration of the scope of the study in animal model. The early marker for CCA diagnosis was discovered in hamster model and apply in the patients. The step include 1) proteomic analysis for protein identification, 2) Raman spectroscopy based on based line peak, SERS from NECTEC and SERS from EN-KKU, and 3) histopathological study by staining with hematoxylin-eosin (H&E), cytokeratin-19 (CK-19) and alpha-fetoprotein (AFP).




Fig.4 CCA development is classified into inflammation, pre-cancerous lesion and tumor lesion according to histopathological changes




Fig.5 Comparison among principle components analysis (PCA) results of Raman spectra of four classes of normal, inflammation, pre-cancerous and tumor. However, Raman intensities couldn't distinguish between pre-cancerous and CCA groups based on classical machine (ML) algorithm.




Fig.6 Comparison among Raman peak based on classical machine (ML) algorithm of four classes based on normal, inflammation, pre-cancerous and tumor features.

	precision	recall	f1-score	support
Group 1-N	0.61	0.84	0.71	231
Group 2-I	0.40	0.07	0.11	61
Group 3-P	0.61	0.51	0.56	210
Group 4-C	0.65	0.65	0.65	220
accuracy			0.62	722
macro avg	0.57	0.52	0.51	722
weighted avg	0.61	0.62	0.60	722

SERS couple with PCA couldn't distinguish precancerous-tumor lesion and yield accuracy of test 62%.

The integration of SERS and machine learning achieved a diagnostic sensitivity of 93%, specificity of 95%, and accuracy of $\geq 67\%$ for precancerous lesions and CCA

Project activities: MDKKU-ENKKU




Fig.7 Different staging of CCA development was established.




Fig.10 ROC curves analysis the performance of various classification models. The DWT + 2D CNN model achieved an AUC of 0.95, which gave the highest accuracy performance for CCA diagnosis compared to the other models.




Fig.11 Confusion matrices of each signal processing and machine learning methods by 2D CNN.




Fig.8 Illustration of study design for SERS+AI marks early stage of CCA




Fig.9 Raman peak identifies the different staging of inflammation, precancerous (Pre-CA) and CCA lesions

DWT = discrete wavelet transform

Method	Accuracy (%)	Sensitivity (Recall) (%)	Specificity (%)	F1 Score (%)
DWT + 2D CNN	95.10	95.08	98.36	95.10
DWT + 1D CNN	92.00	91.50	96.00	91.75
PCA + 1D CNN	88.00	87.50	94.00	87.75
LDA + SVM	84.50	84.00	90.50	84.25
PCA + SVM	82.40	82.00	88.40	82.20


Accuracy 95%, sensitivity 95%. Specificity 96%

Raman spectrometry coupled with machine learning, especially, 2D CNN, could distinguish stage-specific for CCA development for normal, inflammation, pre-cancerous and tumor, but doesn't by classical machine learning of Raman intensity. Integrative SERS with 2D CNN explores high accuracy performance for early CCA diagnosis, which can apply for a mobile application use.


Project activities: **ENKKU**: Biosensing platform based on SERS

Biosensing platform development based on Raman spectroscopy techniques

Surface Enhance Raman Spectroscopic (SERS) chip development



SERS chip using (a) 3D microporous graphene (Srichan *et al.*, 2016) (b) Silver nanorods fabricated by glancing angle method (Botta *et al.*, 2018) (c) electrochemically synthesized silver nanowires (Fang *et al.*, 2012) (d) Hot spot model as one of the mechanisms behind Raman signal enhancement (Radziuk & Moehwald, 2015).



(a) Raman peak selection for a specific analyte (Srichan *et al.*, 2016), (b) designed portable SERS-based sensor for early CCA detection (this proposal).

Highly Accurate and Robust Early Stage Detection of Cholangiocarcinoma Using Near-Lossless SERS Signal Processing with Machine Learning and 2D CNN for Point-of-care Mobile Application



Pobporn Danvirutai, Thatsanapong Pongking, Suppakrit Kongsintaweek, Somchai Pinlaor, Sartra Wongthanavasu, and Chavis Srichan*

Cite This: *ACS Omega* 2025, 10, 11296–11311

[Read Online](#)

[ACCESS |](#) [Metrics & More](#) | [Article Recommendations](#) | [Supporting Information](#)

ABSTRACT: Introduction: Cholangiocarcinoma (CCA), a malignancy of the bile ducts, presents a significant health burden with a notably high prevalence in Northeast Thailand, where its incidence ratio is 85 per 100,000 population per year. The prognosis for CCA patients remains poor, particularly for proximal tumors, with a dismal 5-year survival rate of just 10%. The challenge in managing CCA is exacerbated by its typically late detection, contributing to a high mortality rate. Current screening methods, such as ultrasound, are insufficient, as many CCA patients do not exhibit prior symptoms or detectable liver fluke (*Opisthorchis viverrini*: OV) infections, underscoring the urgent need for alternative early detection methods. Methods: In this study, we introduce a novel approach utilizing surface-enhanced Raman spectroscopy (SERS) combined with near-lossless signal compression via discrete wavelet transform (DWT) together with 2D CNN for the first time. Hamster serums of different stages were collected as the data set. DWT was employed for feature extraction, enabling the capture of the entire SERS spectrum, unlike traditional methods like PCA and LDA, which focus only on specific peaks. These features were used to train a 2D convolutional neural network (2D CNN), which is particularly robust against translation, rotation, and scaling, thus effectively addressing the SERS peak shifting issues. We validated our approach using gold-standard histology, and notably, our method could detect CCA at an early stage. The ability to identify CCA at the early stage significantly improves the chances of successful intervention and patient outcomes. Results and conclusion: Our results demonstrate that our method, combining SERS with extremely compact wavelet feature extraction and 2D CNN, outperformed other approaches (PCA + SVM, PCA + 1D CNN, PCA + 2D CNN, LDA + SVM, and DWT + 1D CNN), achieving performance of 95.1% accuracy, 95.08% sensitivity, 98.4% specificity, and an area under the curve (AUC) of 95%. The trained model was further deployed on a server and mobile application interface, paving the way for future field experiments in rural areas and home-use potential point-of-care services.






Project activities: **ENKKU**: Biosensing platform based on SERS

Surface Enhance Raman Spectroscopic (SERS) chip development






Part I: Synthesis of AuNPs and novel techniques to pair nanoparticles to yield greatest enhancement

1. Software license
2. (Q1) ACS OMEGA
3. (Scopus-index) Conference paper to appear in IEEEXplore





+ carried out characterization on TEMs, SEM, processing technique, etc. (Figures will be licensed under publisher)

Novel Gold Nanoparticles with 1nm gap for optimized SERS Enhancement




Project activities: MDKKU-BIOTEC





Proteomics discovery Olf4, SMC2, B4GALT4 for CCA diagnosis



Partial Least Squares Discriminant Analysis (PLS-DA) analysis






Heatmap



In progress to verify in human samples

Project activities: **MDKKU-BIOTECH**; Sample collection, identification and evaluation of biomarker in CCA patients







Determination of β -HCG levels in human serum. Serum β -HCG levels in healthy (N=60), Bening biliary disease (N=52), and CCA patient (N=100) were determined using electrochemiluminescence immunoassay. * P<0.05 compared with healthy group. #P<0.05 compared with BBD group.

Immunohistochemical staining for β -HCG in cholangiocarcinoma and adjacent tissues. Staining pattern of the TMA section (A). Immunoreactive positive area (%) in cancerous tissues was higher than in adjacent tissues (B). Images showing β -hCG staining in CCA (C), and adjacent tissues (D). ** P<0.001 compared with adjacent tissue.

Raman peak separates serum CCA from the patients from normal serum by Raman spectroscopy. Upper line is CCA, and under line is normal.

Project activities: MDKKU-BIOTECH, Identification and evaluation of biomarker in CCA patients




ROC analysis results when combined HCG, AFP, CEA and CA19-9

Project activities: MDKKU/NECTEC; Raman spectrum detection and Machine learning training

Human samples analysis (n=221): CCA = 71, HCC = 50, LM = 50, HA = 50


Combination of SERS and silver nanorod substrate with LDA could effectively identify and differentiate CCA from healthy subjects and patients with other liver malignancies with **81% accuracy and 0.97 of AUC values.**



Valid data (n=194) : CCA = 58, HCC = 48, LM = 44, HA = 44


(a) Mean Raman spectra $\pm$ standard deviation for all four groups: normal control (NC, n = 44, pink), liver metastases (LM, n = 44, purple), hepatocellular carcinoma (HCC, n = 48, orange), and cholangiocarcinoma (CCA, n = 58, green). Each spectrum represents the averaged SERS signal for the respective group.

(b) Mean Raman spectra $\pm$ standard deviation grouped into two categories: normal control (NC, orange) and combined liver cancer samples (CCA + HCC + LM, green). The spectral differences between the normal and cancer groups highlight key Raman shifts relevant for distinguishing healthy and malignant samples.




(a) 3D Scatter Plot of Principal Component Analysis (PCA) Components: Visualization of Raman spectral data projected onto three principal components, showing the distribution of different groups: normal control (NC, blue), cholangiocarcinoma (CCA, light blue), hepatocellular carcinoma (HCC, yellow), and liver metastases (LM, red). The clustering pattern suggests some separation between the groups.

(b) 2D Scatter Plot of Linear Discriminant Analysis (LDA) Components: LDA was applied to maximize class separability in the spectral data, resulting in distinct clustering of the four groups. The improved separation compared to PCA indicates the effectiveness of LDA in distinguishing between normal and cancerous samples.




The ROC curves represent the classification performance of the Linear Discriminant Analysis (LDA) model in differentiating between the four groups: normal control (NC), cholangiocarcinoma (CCA), hepatocellular carcinoma (HCC), and liver metastases (LM). The area under the ROC curve (AUC) values for each class indicate the model's ability to distinguish between groups, with higher AUC values reflecting better classification performance. The diagonal dashed line represents a random classifier (AUC = 0.5) for reference. The LDA model demonstrates high classification accuracy, particularly for distinguishing normal and cancerous samples, supporting the effectiveness of SERS-based machine learning for liver cancer detection.


Project activities: **MDKKU/BIOTEC**; Protein identification in participants serum



The Venn diagram illustrates the overlap of differentially expressed proteins among the four groups: **cholangiocarcinoma (CCA, red)**, **hepatocellular carcinoma (HCC, yellow)**, **liver metastases (LM, green)**, and **healthy controls (cyan)**. The numbers within each section represent the count of unique or shared proteins between the groups. The central region (7820) indicates the core set of proteins common across all groups, while peripheral numbers highlight proteins uniquely expressed in each condition. This analysis provides insights into shared and distinct molecular features among liver cancer subtypes and healthy individuals, aiding in biomarker discovery for disease classification.



The PCA score plot visualizes the clustering patterns of different sample groups based on their principal component scores. Each point represents an individual sample, color-coded by group: **cholangiocarcinoma (CCA, red)**, **hepatocellular carcinoma (HCC, green)**, **liver metastases (LM, blue)**, and **healthy control (cyan)**. The ellipses represent the 95% confidence intervals for each group. The clear separation between groups suggests distinct molecular or spectral differences, supporting the potential of PCA in distinguishing liver cancer subtypes from normal samples.



The heatmap represents the expression patterns of selected proteins across four groups: **cholangiocarcinoma (CCA, red)**, **hepatocellular carcinoma (HCC, green)**, **liver metastases (LM, blue)**, and **healthy controls (cyan)**. The color scale indicates normalized protein expression levels, with red representing **upregulated proteins**, blue representing **downregulated proteins**, and white indicating **intermediate expression levels**. The hierarchical clustering on the left groups proteins based on similarity in expression patterns. The observed differences in protein expression suggest potential biomarkers for distinguishing between liver cancer subtypes and normal samples.

Project activities: MDKKU, ENKKU, NECTEC, BIOTEC

Budget usage for the 1st year COMPLETED

Activities	Budget
Hamsters' CCA setting, samples collection and histopathological confirmation	4,000 USD
Discovery of Raman peak for CCA diagnosis	3,000 USD
Patients sample collection	2,500 USD
Identification & evaluation of biomarker in CCA patients: training set	3,500 USD
Verification of electrochemical sensor for CCA diagnosis: verification set	3,000 USD
SERS development: Synthesis	4,000 USD
SERS development: Characterization	1,000 USD
Total	21,000 USD

Budget usage for the 2nd year COMPLETED

Activities	Budget
Sample collection and providing standard protein & antibody for CMUs' team	4,000 USD
Proteins panel discovery and identification	7,500 USD
Raman spectrum identification	5,000 USD
Construct AI & Machine learning model	2,000 USD
Transfer technology of SERS and AI for CCA diagnosis to Laos' team	2,500 USD
KKU facilities services	2,100 USD
Total	21,000 USD

Overview of research objectives and activities of CMU

CMU: Biosensing platform based on silicon photonic development

Activities in ASEAN IVO 2023

- 1. Sensor device design investigation specifically for the detection of CCA biomarker (s)
- 2. Simulation of silicon nitride biosensor devices

Activities in ASEAN IVO 2024

- 1. Prototype sensor system development
- 2. Sensing experiment using samples provided by KKU or Laos
 - Detection of new CCA biomarkers from KKU
 - Comparison with conventional method

(Year 1) Key elements demonstrated in laboratory

(Year 2) Device manufacturing & performance assessment using standard testing method

Budget usage	Budget
Survey report of the photonic sensor technologies that are applicable to cholangiocarcinoma detection.	\$3000 ✓
investigation of new photonic sensor design and simulation results using numerical based simulation.	\$3000 ✓
Computer-aided design (CAD) drawing of silicon photonic sensor mask design	\$1500 ✓

✓ COMPLETED


Budget usage	Budget
Photonic (resonator) sensor devices and a prototype of the measuring system	\$7000 ✓
Project workshop and meeting	\$3500 ✓

✓ COMPLETED

2024 PROGRESS

CMU: Biosensing platform based on silicon photonic development

Fabrication of silicon photonic sensors






Photomask designs submitted to manufacturer (TMEC) **August 2024**

Fabricated sensors expected by **March 2025**

Development of New sensor measurement system prototype

Proof of concept In Laboratory

broadband source



MEMS filter

Power Meter

September 2024

Measurement system prototype and sensors purchase order

October 2024 – March 2025

The project will order a developer to created a system based on the laboratory concept with software control

Tech transfer (workshop in CMU, demo of the prototype)

CCA detection test (Pending samples provided by KKU and Laos Team)

February 2025

COMPLETED

Project activities: **LAOS** ; Biosensing platform for clinical application

Biosensing potable platform for clinical sample of Laos CCA patients in various specimens



✓ COMPLETED

Budget plan for year 1st

Budget usage	Budget
Freezer	\$6,000
Total	\$6000

Budget plan for year 2nd

Budget usage	Budget
Collection of various samples from the patients: healthy, CCA, HCC, and other cancers; materials, volunteer compensation, physician, surgeon, etc.,	\$2500
Identification & evaluation of biomarker in CCA patients: training set	\$1500
Total	\$4000


Collect and verify CCA samples: urine, serum

✓ COMPLETED

Project activities: LAOS ; Biosensing platform for clinical application

Biosensing potable platform for clinical sample of Laos CCA patients in various specimens

Spatial Distribution of Cancer Cases in Hospital registries in Laos PRD





5. Transfer technology of SERS and AI for CCA diagnosis to Laos' team


Transportation Laos' samples to KKU




Detection of Serum Using Raman Spectroscopy



Distribution of dat.laos\$year



The raw Raman data and an example of the Raman peak results.



Phase II



Project activities: **Workshop on Nov 13-16, 2023 at Vientiane, LAOS**



Project Activities: **Workshop on June 20-21, 2024 at KKU, Thailand**


BAYASITA HOTEL
 123 Mittraphap Rd., Muang District,
 Khon Kaen 40002, Thailand



OPEN WORKSHOP FOR
INNOVATION OF PHOTONIC AND ELECTROCHEMICAL BIOSENSORS FOR CHOLANGIOCARCINOMA DIAGNOSIS

 **Date :**
 June 20th-21st, 2024

 **Time :**
 8:00 am - 5:00 pm



PLEASE JOIN US



SPEAKERS

 Prof. Shosuke Kawanishi Suzuka University of Medical Science	 Prof. Tetsuya Kawanishi Khon Kaen University	 Prof. Nipon Theera-Umpon Director of Biomedical Engineering Institute, CMU
 Assoc. Prof. Chawalit Pairojkul Khon Kaen University	 Prof. Somchai Pintaor Khon Kaen University	 Assoc. Prof. Raynoo Thanan Khon Kaen University
 Assist. Prof. Chavis Srichan Khon Kaen University	 Assist. Prof. Chodamas Sakonsinsiri Khon Kaen University	 Dr. Sittiruk Roytrakul BCTEC
 Dr. Kaulchi Akahane National Institute of Information and Communications Technology	 Dr. Noppadon Nuntawong BCTEC	 Dr. Nithi Atthi BCTEC
 Ms. Aye Myat Mon Khon Kaen University	MODERATORS  Dr. Apisit Chaldee Khon Kaen University	
 Ms. Phonplais Thongpon Khon Kaen University		


Department of Parasitology, Faculty of Medicine, Khon Kaen University, Thailand
This symposium is the output of the ASEAN IVO (http://www.asean-ivo.org) project, Development of photonic and electrochemical biosensors for cholangiocarcinoma diagnosis.



Project activities: **Workshop on Feb 18, 2025 at CMU, Thailand**



WORKSHOP FOR INNOVATION OF PHOTONIC & ELECTROCHEMICAL BIOSENSORS FOR CHOLANGIOCARCINOMA DIAGNOSIS

18 FEB 2025
8:30 - 15:00

The workshop provides a comprehensive update on cholangiocarcinoma (CCA) research and the latest developments in electrochemical and photonic biosensors. It also serves as the concluding activity of the ASEAN IVO project. The ICT Virtual Organization of ASEAN Institutes and NICT (ASEAN IVO) stand as a global alliance of ICT R&D institutes and the universities across the ASEAN region and Japan.

SPEAKERS

- PROF. NIPON THEERA-UMPON (CHANG MAI UNIVERSITY)
- PROF. SOMCHAI PINLAOR (KHON KAEN UNIVERSITY)
- DR. CHAMPADENG VONGDALA (CANCER CENTER, LAOS)
- DR. PITAK EIAMCHAI (NATIONAL ELECTRONICS AND COMPUTER TECHNOLOGY CENTER)
- DR. SITTIRUK ROYTRAKUL (NATIONAL CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY)
- DR. CHAVIS SRICHAN (KHON KAEN UNIVERSITY)
- DR. UKRIT MANKONG (CHANG MAI UNIVERSITY)
- DR. NITHI ATTHI (THAI MICROELECTRONICS CENTER (INVITED SPEAKER))
- DR. YOSHINARI AWAJI (NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY)

Sponsored by **IRCT**



Project activities: **Progress review at CMU, Thailand**



Dr.Emoto Hiroshi (NICT)
Yoshihiro Sakuda (NICT Asia center, BBK, Thailand)
Assoc.Prof.Sansanee Auephunviriyakul (CMU)
Assoc.Prof.Ukrit Mankong (CMU)
Dr.Suruk Udomsom (CMU)
Prof.Somchai Pinlaor (KKU)

Group discussion at CMU, 27 Dec 2024



Project activities: ASEAN IVO **project review at LAOS and Cambodia**

ASEAN IVO Forum 2023, 15-16 Nov 2023



6 months Review & Report, 15-16 Nov 2023, LAO



ASEAN IVO Forum 2024, 7-9 Nov 2024, Camdodia



1st Year Review & Report, 7-9 Nov 2024, at Phnom Penh



4 Directors of NICT have visited and discussed at MD-KKU for next project activity



NICT


20 November 2024

1. **Hiroaki Harai** (Director General of Network Research Institute)
2. **Tetsuya Kawanishi** (Research Executive Director, Prof. of Waseda University)
3. **Yoshinari Awaji** (Director General of Photonic ICT Research Center)
4. **Kouichi Akahane** (Director of Optical Access Technology Laboratory)
5. **Toshimasa Umezawa** (Senior Researcher of Optical Access Technology Laboratory)
6. **Atsushi Matsumoto** (Senior Researcher of Optical Access Technology Laboratory)



R&D results: ENKKU-MDKKU; Biosensing platform development based on Raman spectroscopy techniques.

ENKKU: Surface Enhance Raman Spectroscopic (SERS) chip development.



<http://pubs.acs.org/journal/acscodf>

This article is licensed under [CC-BY-NC-ND 4.0](#)

Highly Accurate and Robust Early Stage Detection of Cholangiocarcinoma Using Near-Lossless SERS Signal Processing with Machine Learning and 2D CNN for Point-of-care Mobile Application

Pobporn Danvirutai, Thatsanapong Pongking, Suppakrit Kongsintaweek, Somchai Pinlaor, Sartra Wongthanavasu, and Chavis Srichan*

Cite This: *ACS Omega* 2025, 10, 11296–11311

[Read Online](#)

[ACCESS |](#)

[Metrics & More](#)

[Article Recommendations](#)

[Supporting Information](#)

ABSTRACT: Introduction: Cholangiocarcinoma (CCA), a malignancy of the bile ducts, presents a significant health burden with a notably high prevalence in Northeast Thailand, where its incidence ratio is 85 per 100,000 population per year. The prognosis for CCA patients remains poor, particularly for proximal tumors, with a dismal 5-year survival rate of just 10%. The challenge in managing CCA is exacerbated by its typically late detection, contributing to a high mortality rate. Current screening methods, such as ultrasound, are insufficient, as many CCA patients do not exhibit prior symptoms or detectable liver fluke (*Opisthorchis viverrini*: OV) infections, underscoring the urgent need for alternative early detection methods. Methods: In this study, we introduce a novel approach utilizing surface-enhanced Raman spectroscopy (SERS) combined with near-lossless signal compression via discrete wavelet transform (DWT) together with 2D CNN for the first time. Hamster serums of different stages were collected as the data set. DWT was employed for feature extraction, enabling the capture of the entire SERS spectrum, unlike traditional methods like PCA and LDA, which focus only on specific peaks. These features were used to train a 2D convolutional neural network (2D CNN), which is particularly robust against translation, rotation, and scaling, thus effectively addressing the SERS peak shifting issues. We validated our approach using gold-standard histology, and notably, our method could detect CCA at an early stage. The ability to identify CCA at the early stage significantly improves the chances of successful intervention and patient outcomes. Results and conclusion: Our results demonstrate that our method, combining SERS with extremely compact wavelet feature extraction and 2D CNN, outperformed other approaches (PCA + SVM, PCA + 1D CNN, PCA + 2D CNN, LDA + SVM, and DWT + 1D CNN), achieving performance of 95.1% accuracy, 95.08% sensitivity, 98.4% specificity, and an area under the curve (AUC) of 95%. The trained model was further deployed on a server and mobile application interface, paving the way for future field experiments in rural areas and home-use potential point-of-care services.

ACKNOWLEDGMENT

We acknowledge the funding support from NICT, Japan, under the ASEAN IVO 2023 Project, "Innovation of Photonic and Electrochemical Biosensors for Cholangiocarcinoma Diagnosis." Special thanks are extended to Dr. Sirinapa Klungaeng for her contributions during the initial phase of this work. Collaborations with NECTEC team through Dr. Pitak Eiamchai and Dr. Noppadon Nuntawong are greatly appreciated.

Received

1. Software license
2. (Q1) Article published on ACS OMEGA]
3. (Scopus-index) Conference paper to appear in IEEE Xplore



ทะเบียนข้อมูลเลขที่ 71.011364

คำขอแจ้งข้อมูลเลขที่ 446105

หนังสือแสดงการแจ้งข้อมูลลิขสิทธิ์

ออกให้เพื่อแสดงว่า

มหาวิทยาลัยขอนแก่น

ได้แจ้งข้อมูลลิขสิทธิ์ไว้ต่อกรมทรัพย์สินทางปัญญา

เมื่อวันที่ 5 เดือน สิงหาคม พ.ศ. 2567

ประธานงาน กรรมการ สภามหาวิทยาลัยขอนแก่น

ชื่อผลงาน โปรแกรมประยุกต์บนสมาร์ทโฟนและคอมพิวเตอร์สำหรับแยกแยะ

ภาพระยะเรื้องหน้าผ่านสัญญาณรบกวนโดยใช้เทคนิคแมชชีนเลิร์นนิง

(Mobile and Desktop Application for Raman Signal Classification

for Cholangiocarcinoma Stage Identification using Multiresolution

Feature Extraction and Deep Neural Networks)

ออกให้ ณ วันที่ 11 เดือน กันยายน พ.ศ. 2567

ลงชื่อ.....

(นางสาวศิริวรรณ นพรัตน์)

นักวิชาการพาณิชย์ปฏิบัติการ

ปฏิบัติราชการแทนผู้อำนวยการกองลิขสิทธิ์



หมายเหตุ เอกสารนี้มิได้รับรองความเป็นเจ้าของลิขสิทธิ์

ในกรณีมีข้อพิพาททางลิขสิทธิ์เป็นผู้นิยามชี้ขาดความเป็นเจ้าของลิขสิทธิ์

Signed by DIP-CA

R&D results: CMU

CMU: Designed and developed photonic sensor device for CCA diagnosis.



Sensing results: Laboratory proof of concept of the prototype

Next step CCA biomarker test

Scientific contribution:

Presentations at International Conferences:

No:	Paper title:	Author names	Affiliation	Conference	Date	Venue
1	Early diagnosis of cholangiocarcinoma using surface-enhanced Raman spectroscopy combined with AI in a hamster model	Somchai Pinlaor a,b, Chavis Srichanc, Pobporn Danvirutaid, Kitti Intuyodb,e, Apisit Chaideea,b, Chawalit Pairojkuleb,e, Thatsanapong Pongking b,f, Suppakrit Kongsintaweesuk b,f , Mati Horprathumg, Pitak Eiamchaig, Saksorn Limwicheang, Noppadon Nuntawongg	^a Department of Parasitology, Faculty of Medicine, and ^b Cholangiocarcinoma Research Institute, ^c Faculty of Engineering, ^d College of Computing, ^e Department of Pathology, Faculty of Medicine, ^f Biomedical Sciences Program, Khon Kaen University, Khon Kaen 40002, Thailand. ^g National Electronics and Computer Technology Center (NECTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani, Thailand	The 83rd Annual Meeting of the Japanese Cancer Association (JCA2024)	September 19 (Thu.) - 21 (Sat.), 2024	Fukuoka, Japan

Published Journal Papers:

No:	Paper title:	Author names	Affiliation	Journal name:	Publisher	Volume number and Pages	
1	Highly Accurate and Robust Early Stage Detection of Cholangiocarcinoma Using Near-Lossless SERS Signal Processing with Machine Learning and 2D CNN for Point-of-care Mobile Application	Pobporn Danvirutai, Thatsanapong Pongking, Suppakrit Kongsintaweesuk, Somchai Pinlaor, Sartra Wongthanavas, Chavis Srichan*	¹ College of Computing, Khon Kaen University, Khon Kaen 40002, Thailand ² Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. ³ Cholangiocarcinoma Research Institute, Faculty of Medicine, Khon Kaen University, Thailand ⁴ Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand ⁵ Department of Computer Engineering, Faculty of Engineering, Khon Kaen University, Khon Kaen 40002, Thailand. ⁶ Department of Biomedical Engineering, Faculty of Engineering, Khon Kaen University, Khon Kaen 40002, Thailand..	ACS OMEGA	ACS Publisher	Vol 10, Issue 11, March, 2025	• •

Animal Raman

PLOS ONE

Minimally invasive detection for an early stage of opisthorchiasis-associated cholangiocarcinoma using label-free surface-enhanced Raman spectroscopy (SERS)
--Manuscript Draft--

Manuscript Number:	
Article Type:	Research Article
Full Title:	Minimally invasive detection for an early stage of opisthorchiasis-associated cholangiocarcinoma using label-free surface-enhanced Raman spectroscopy (SERS)
Short Title:	Label-Free SERS Detects Early Opisthorchiasis-Associated CCA
Corresponding Author:	Somchai Pinlaor, PhD Khon Kaen University Amphoe Mueang, Khon Kaen THAILAND
Keywords:	Bile-duct cancer; biosensor; Raman spectroscopy; Artificial intelligence; cancer staging
Abstract:	Cholangiocarcinoma (CCA) is a deadly cancer often detected late. Current diagnostic methods, such as ultrasound and invasive biopsies, have limitations; there is a critical need for a rapid, minimally invasive, and effective strategy for the early diagnosis and staging of CCA. We aimed to address this need using serum samples and label-free surface-enhanced Raman spectroscopy (SERS) combined with machine learning. CCA development was induced in hamsters using a combination of Opisthorchis viverrini infection and administration of N-nitrosodimethylamine with induction time courses spanning 1–5 months (s). Normal and pathological stages (inflammation, precancerous lesion, and CCA) were assigned based on histopathological features, as well as the expression of cytokeratin 19 and alpha-fetoprotein. Raman spectra were subjected to dimensionality reduction using principal component analysis, and diagnostic clusters were acquired using partial least-squares discriminant analysis. For pathological staging, the integration of SERS and machine learning achieved a diagnostic sensitivity of 93%, specificity of 95%, and accuracy of $\geq 67\%$ for precancerous lesions and CCA, with an area under the receiver operating characteristic curve exceeding 0.67. These results have significant potential for accurately detecting the precancerous and cancerous stages of bile-duct neoplasms in the hamster model. Further development of this cost-effective, label-free SERS approach is likely to be ideal for community-based CCA screening.
Order of Authors:	Apisit Chaidee, PhD Suppakrit Kongsintaweek, MSc. Thatsanapong Pongking, PhD Keerapach Tunbenjasiri, MSc Aye Myat Mon, Msc. Chawalit Pairojkul, PhD Pakornkiat Tanasuka, BSc. Tullayakorn Plengsuriyakarn, PhD Kesara Na-Bangchang, PhD David Blair, PhD Nanuechar Charoenram, Bsc. Somchai Pinlaor, PhD
Opposed Reviewers:	
Additional Information:	
Question	Response

Human Raman

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

Surface-enhanced Raman spectroscopy and machine learning differentiate specific liver cancers

Journal:	ACS Applied Nano Materials
Manuscript ID	Draft
Manuscript Type:	Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Intuyod, Kitt; Khon Kaen University Faculty of Medicine Kongsintaweek, Suppakrit; Khon Kaen University, Biomedical sciences program, Graduate school Eiamchai, Pitak; National Electronics and Computer Technology Center, Luvira, Vor; Khon Kaen University, Department of Surgery, Faculty of Medicine Chaidee, Apisit; Khon Kaen University, Department of Parasitology, Faculty of Medicine Techasen, Anchalee ; Khon Kaen University, Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Pinlaor, Pornpip; Khon Kaen University Pairojkul, Chawalit; Khon Kaen University, Department of Pathology, Faculty of Medicine Blair, David; James Cook University Umezawa, Toshimasa; National Institute of Information and Communications Technology (NICT) Matsumoto, Atsushi; Kyushu University Akahane, Kouichi; National Institute of Information and Communications Technology horprathum, mati; National Electronics and Computer Technology Center, Opto-Electrochemical Sensing Research Team Limwichan, Saksorn ; National Electronics and Computer Technology Center Nuntawong, Noppadon; National Electronics and Computer Technology Center, Pinlaor, Somchai; Khon Kaen University, Department of Parasitology

Biomarker in human serum

Advances in Medical Sciences

Development and clinical validation of a β -hCG-based panel for cholangiocarcinoma screening: from proteomics to clinical validation
--Manuscript Draft--

Manuscript Number:	
Article Type:	Original Article / Research
Keywords:	Bile-duct cancer, Biomarker, Liver cancer, Tumor interstitial fluid
Corresponding Author:	Pornpip Pinlaor, PhD Khon Kaen University THAILAND
First Author:	Suppakrit Kongsintaweek
Order of Authors:	Suppakrit Kongsintaweek Thatsanapong Pongking Keerapach Tunbenjasiri Pakornkiat Tanasuka Sitiruk Roytrakul Sudarat Onsurathum Chawalit Pairojkul Kitti Intuyod Vor Luvira David Blair Somchai Pinlaor Pornpip Pinlaor, PhD
Abstract:	Purpose: Opisthorchis viverrini-associated cholangiocarcinoma (CCA) in Northeast Thailand is marked by late diagnosis and poor prognosis, creating a critical need for effective early-detection biomarkers. This study aimed to identify a novel glycoprotein biomarker panel from tumor interstitial fluid (TIF) to improve CCA screening. Materials/Methods: Glycoprotein-enriched TIF and paired normal interstitial fluid samples from three CCA patients were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Given its increase in various cancers, the protein expression of beta-human chorionic gonadotropin (β-hCG) was assessed using immunohistochemistry (IHC) in a tissue array of 100 CCA samples. Serum levels of β-hCG, carbohydrate antigen 19-9 (CA 19-9), alpha-fetoprotein (AFP), and carcinoembryonic antigen (CEA) were quantified in 405 individuals, including patients with CCA (n=153), other hepatobiliary diseases, and healthy controls. Performance of β-hCG in screening for CCA was evaluated. Results: Proteomic analysis identified elevated β-hCG specifically in TIF from CCA patients. IHC confirmed significantly higher β-hCG expression in tumor tissues compared to adjacent non-tumor areas ($p < 0.0001$). Serum β-hCG levels were significantly increased in CCA patients and correlated with tumor volume and reduced survival ($p < 0.05$). While β-hCG alone had limited diagnostic performance, a combined panel adding CA 19-9, CEA, and AFP yielded excellent diagnostic accuracy (AUC: 0.962; sensitivity: 86%; specificity: 100%). Conclusions: β-hCG is a valuable prognostic marker for CCA and in a multi-marker panel significantly enhances diagnostic performance. This panel shows strong potential for improving the early detection and prognostic evaluation of CCA, warranting large-scale validation for clinical application.
Opposed Reviewers:	

Societal impact:

1. One license for SERS signal processing using multiresolution compression and convolutional neural networks
2. Sharing proteomics data: The accession numbers are PXD057256 for ProteomeXchange and JPST003438 for jPOST.
3. **Sharing Raman data** : **Mendeley: DOI: 10.17632/8gs6tc6vgr.1 (Animal)**
Mendeley: DOI:10.17632/hzg43f63k9.1. (Human)
4. Two international publications
 - SERS with DWT and CNN for CCA diagnosis (ACS Omega, 10;11,2025)—Q1
 - Proceeding on international conference on BMiCON 2024 (online)
5. **Four manuscripts** have been submitted & revised on Q1 journal
 - SERS diagnosis in hamsters' serum (PLOS ONE, revised)
 - SERS diagnosis in patients' serum (ACS Applied Nano Materials, revised)
 - Colloidal SERS for CCA diagnosis (ACS Omega, under review)
 - beta-HCG marks for CCA diagnosis (Advances in Medical Sciences, under review)
6. Two international conferences:
 - The 83rd Annual Meeting of the Japanese Cancer Association (JCA) on September 19-21, 2024 at Fukuoka, Japan (poster presentation)
 - International conference on BMCiCON 2024, 21-24 Nov 2024, Pattaya, Thailand (Oral presentation)
7. **Manuscript preparation: INPROGRESS**
 - **Incidence of cancer in Lao PDR** (The Lancet Regional Health - Southeast Asia, will be submitted)
 - **Proteomics identified candidate markers for CCA diagnosis** (Manuscript preparation)

• • •
• • •
• • •
• • •
• • •
• • •
• • •
• • •
• • •
• • •

Activity and budget planning in the 2nd year

No	Activities	Budget (US)	Responsibility	Out put
1	1. Sample collection and Std protein & ab for CMUs' team 2. Proteins panel discovery 3. Raman spectrum identification 4. Construct AI & Machine learning 5. Transfer technology of SERS and AI for CCA diagnosis to Laos' team	21,000	KKU (MD & EN) BIOTECH NECTEC	- Samples of CCA, HCC, metastasis liver and healthy subjects collection, -At least 1 publication -1 patent/pretty patent
2	Optical sensing development: equipment, materials, research exchange at NICT	7,000	CMU	-1 publication
3	Human sample & clinical data collection: Surgery team & pathology team for samples collection, biobank, histopathological study, freezer, equipment, etc.,	4,000	Laos	Team initiation, CCA sample & other cancer sample collection
4	Project meeting or workshop at the end of the 2 nd year	3,000	KKU for all team (CMU-KKU-Laos)	Meeting & conference: 1 session for biosensor for CCA diagnosis
5	Project meeting or workshop at the end of the 2 nd year	3,500	CMU for all team (CMU-KKU-Laos)	Meeting & conference: 1 session for biosensor for CCA diagnosis
6	Project meeting and report (estimate)	1,500	KKU team	Attend on Campodia, 6-7 Nov 2024
Total		40,000		

Two years timeline schedule

Institution	Research activity	2023												2024											
		4	5	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3
MD-KKU, NECTEC, BIOTECH	Supplies & Materials: Animal model setting, equipment, samples collection, Raman spectrometer finger print																								
EN-KKU,	SERS chip development : equipment & materials, SERS substrate synthesis and design of portable CCA specific SERS-based sensor, training with NICT																								
CMU	Optical sensing development: equipment, materials, training with NICT																								
MD-KKU	Surgery team & pathology team for samples collection, biobank, histopathological study, standard method confirmation by ELISA & WB																								
Lao PDR	Surgery & pathology team management, workshop, training, samples collection, prototype evaluation, team meeting and conference																								
MD-KKU, EN-KKU, CMU, BIOTECH, NECTEC, TMEC, Laos, NICT	Meeting and conference, transport, report, publication, biosensing prototype																								

Phase II



Thank you

